Examining the HER2 Testing Puzzle: Fresh Research Explores Nagging Questions

Posted on March 26th, 2012 by

In the more than 30 years since the human epidermal growth factor receptor 2 (HER2) gene was first successfully explored, HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies…The issues at stake are vital not only to patients with breast cancer but also to those with other tumor types, noted Edith A. Perez, MD, deputy director of the Mayo Clinic Cancer Center and a professor of Medicine at Mayo Medical School in Jacksonville, Florida.

 

 

OncLive by Anita Shaffer   3/26/12

Tags: Breast Cancer, Dr. Edith Perez, HER2, Issues, Mayo Clinic Cancer Center, Mayo Clinic Jacksonville

You must be logged-in to the site to post a comment.

Contact Us · Privacy Policy